BioSpace News Archive

NHS Greater Glasgow and Clyde Health Board, the largest NHS organization in Scotland and one of the largest in the UK, has joined the TriNetX global health research network to better leverage its extensive patient data and to promote its participation in clinical trials and research.

Brains Bioceutical Corp., One of the rare few EU-GMP Certified CBD API producers in the UK awarded a Schedule 1 Controlled Drug Licence by the UK Home Office, maintaining our industry leading advantage for Cannabinoid based medicines

MET642 Demonstrated Sustained Pharmacokinetic Profile and Robust FXR Target Engagement with Once-Daily Oral Dosing, without Pruritis or LDL-Cholesterol Increase Doses Selected for Phase 2a Trial in Patients with NASH; On-Track to Initiate in 1H21

Horizon Therapeutics plc Announces Short-Term TEPEZZA ® (teprotumumab-trbw) Supply Disruption Due to Government-Mandated (Operation Warp Speed) COVID-19 Vaccine Production

Surface Oncology (Nasdaq: SURF) today announced an agreement for GSK to exclusively license worldwide development and commercial rights to Surface Oncology’s preclinical program SRF813, a fully human IgG1 antibody targeting PVRIG (also known as CD112R), an inhibitory protein expressed on natural killer cells (NK cells) and T cells.

ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced U.S. Food and Drug Administration (FDA) approval and the launch of Aminocaproic Acid Tablets USP, 500mg.

Sonnet BioTherapeutics Holdings, Inc. , a biopharmaceutical company developing innovative targeted biologic drugs, announced today its financial results for the fiscal year ended September 30 th , 2020 and provided a business update.

TransEnterix, Inc. (NYSE American:TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that Southern Surgical Hospital has entered into an agreement to lease and utilize a Senhance® Surgical System.

C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule drugs that selectively destroys disease-causing proteins through degradation, today announced that the Company will be added to the Russell 2000 ® and Russell 3000 ® Indexes as part of the Russell quarterly update, effective December 21, 2020. The Russell 2000 ® Index measures the performance of the small cap segment of the U.

Company to present corporate update and plans for 2021 Topline TRANQUILITY data expected to be reported by mid-January